Aquinox Pharmaceuticals, Inc. (AQXP) Rating Reiterated by Cantor Fitzgerald
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating reiterated by equities researchers at Cantor Fitzgerald in a report released on Thursday. They currently have a $28.00 target price on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 157.35% from the company’s previous close.
The analysts wrote, “FDA advisory committee meeting could shed light on FDA views of IC/BPS. On December 7, the FDA will hold an advisory panel (details here) to discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs” to treat the condition. We believe the meeting could be important to raise awareness of the condition and establish expectations for how IC/BPS drugs should be developed.””
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Thursday, August 10th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Finally, ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $22.50.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded up $0.03 during trading hours on Thursday, hitting $10.88. The company’s stock had a trading volume of 45,900 shares, compared to its average volume of 73,604. Aquinox Pharmaceuticals has a fifty-two week low of $10.68 and a fifty-two week high of $19.97.
COPYRIGHT VIOLATION NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/aquinox-pharmaceuticals-inc-aqxp-rating-reiterated-by-cantor-fitzgerald/1698796.html.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after purchasing an additional 17,455 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after purchasing an additional 11,035 shares during the period. Nexthera Capital LP purchased a new stake in shares of Aquinox Pharmaceuticals in the second quarter valued at approximately $1,276,000. Northern Trust Corp boosted its holdings in shares of Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares during the period. Finally, Sphera Funds Management LTD. boosted its holdings in shares of Aquinox Pharmaceuticals by 21.7% in the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after purchasing an additional 13,450 shares during the period. Hedge funds and other institutional investors own 95.15% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.